Singapore-based SCG Cell Therapy Pte. Ltd has announced the initiation of its global manufacturing and R&D center in Singapore, marking the launch of a first-in-class, closed-off automated cell therapy production system. The new facility, supported by the Singapore Economic Development Board, aims to fully utilize and expand SCG’s capabilities in advanced cell therapy production systems and “off-the-shelf” pluripotent stem cell (iPSC) technology, providing cell therapy products to partner hospitals across the Asia-Pacific, North America, and Europe.
Advanced Cell Therapy Production Systems and iPSC Technology
The production of cell therapy is a complex process involving multiple steps, such as handling highly sensitive “live” cells under strict control conditions. SCG’s proprietary closed-off automated cell therapy production technology revolutionizes the traditional open manual process, offering significant advantages in reducing contamination and risk, improving product consistency and efficiency, increasing scalability, and reducing costs. This advanced system can reduce the clean room space required by each patient by 80%, eliminate labor-intensive programs, and increase production capacity by 10 times. Overall, it is expected to reduce the manufacturing cost per patient by up to 70%, making cell therapy a more affordable treatment option for the majority of patients.
Collaboration and Clinical Verification
In 2021, SCG collaborated with the Cell Therapy Facility of Singapore Health Sciences Authority to validate its proprietary closed-off automated cell therapy production system, which has been clinically verified in Singapore and the US. This collaboration underscores SCG’s commitment to advancing cell therapy technology and ensuring its safety and efficacy.-Fineline Info & Tech
